Premium
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow‐up, prevention and occupational disease
Author(s) -
Leiter Ulrike,
Heppt Markus V.,
Steeb Theresa,
Amaral Teresa,
Bauer Andrea,
Becker Jürgen C.,
Breitbart Eckhardt,
Breuninger Helmut,
Diepgen Thomas,
Dirschka Thomas,
Eigentler Thomas,
Flaig Michael,
Follmann Markus,
Fritz Klaus,
Greinert Rüdiger,
Gutzmer Ralf,
Hillen Uwe,
Ihrler Stephan,
John Swen Malte,
Kölbl Oliver,
Kraywinkel Klaus,
Löser Christoph,
Nashan Dorothee,
Noor Seema,
Nothacker Monika,
Pfannenberg Christina,
Salavastru Carmen,
Schmitz Lutz,
Stockfleth Eggert,
Szeimies RolfMarkus,
Ulrich Claas,
Welzel Julia,
Wermker Kai,
Garbe Claus,
Berking Carola
Publication year - 2020
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.14072
Subject(s) - actinic keratosis , medicine , dermatology , guideline , context (archaeology) , disease , epidemiology , etiology , family medicine , basal cell , pathology , paleontology , biology
Summary Actinic keratoses (AKs) are common lesions in light‐skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence‐based framework for clinical decision making, the guidelines for actinic keratosis and cutaneous squamous cell carcinoma were developed using the highest level of methodology (S3) according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF). The guidelines are aimed at dermatologists, general practitioners, ENT specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office‐based settings as well as other medical specialties involved in the diagnosis and treatment of patients with AKs and cSCC. The guidelines are also aimed at affected patients, their relatives, policy makers and insurance funds. In the second part, we will address aspects relating to epidemiology, etiology, surgical and systemic treatment of cSCC, follow‐up and disease prevention, and discuss AKs and cSCC in the context of occupational disease regulations.